## SUPPLEMENTARY FIGURES



FIG. S1. Evolutionary relationships of primary HIV-1 Nef alleles. The amino acids of the newly amplified Nef alleles were aligned with NA7 (GenBank accession number DQ242535) using ClustalX (41) and amino acids were replaced by codons. Sites with a gap in any sequence were eliminated. The tree was constructed using the neighbor-joining method implemented in ClustalX using Kimura's correction and 1000 bootstrapped replicates. Black asterisks (\*) on branches indicate 100% support for the cluster to the right. Grey asterisks indicate bootstrap support between 97% and 99%. Patient clusters are labeled according to their genotype and viral setpoint as defined in Fig. 1, with red indicating *-35CChi*, blue *-35CClow*, green *-35TThi* and black *-35TTlow* subjects, respectively. Sequences from patient 5466 who was coinfected with two divergent HIV-1 strains are boxed. Scale bar represents 0.02 substitutions per site.

1	Ayristilation		len	gth variable	region			cleavage	acidic	PxxP Moti	f	PPT LTR
Nefcon	MGGKWSKSS	SI V-GWPAVRER	MRRI		-EPAAX	GV GAVSRDLEKH	GAITSSNTAA	XNAD <u>CAW</u> LEA	GEE-EE-VGF	PVRPQVPLRP	MTYKGALDLS	HFLKEKGGLE
5122		.GN		SP-KK- A-	B	<b>.</b>		T A	11171717111			
5542 5565		DG.	IA	DTA RE	T.S	G R	N	NL	···	· • • • • • • • • • • • • •	V SA R	F D D
5661					-PE	RR	TS.	N.P.L	1		A.V	
3551	I I I I I R	.V 11 .G GS	::::A	SP DP-ER- GO				T.P	<u>B</u>			
5549		LG DSI	A	SPTDRV R	AD	A	L	NV				
5958	· · · · · · · · · · · · · ·	·····	A	(P	v	Q	P.	TG	E		G	
5969 6017		.VI	.K.A	3P	V	A	Q м	N.P.V			AI. A.F	
6056	2	чк	A	RPA	E	D		TS	<b>D</b>			
6116		CM ER. A CI		SPT -T	- T. E		P.	N. КА Т	<u>B</u> <del>-</del>	· · K · · · · · · · ·		
6296		.L	· · · · ·		D	Y	N	TA	G		· · · · · · · V · · · ·	
6349		LK	II	PVGE	QGT	QD		T.D.L	<b>E</b>			
6401 3478		KI	:::::	PPEA EF PAPE	G.I	.AQATR	VR	T.PA	<b>AE</b>		E.F	D
5569		V I	A		D			N A		<b>T</b>	A.V	
5319		RVSTI			E			Ŧ	111-11-111			
5527 5541	G		IK	ISAE	-SE	.EQD.	M	NSVR. T	G.			FD
5466		Q	I.Q.I	PLGQ	E	A.QDR.		N.P	<u>D</u>		A.V	
5535		. FS.I	A	SPA	D			TS			A.V	Q
5602 5613	· · · · · · · · · · · · · · · · · · ·	.S L-KI V -	· · · · ·	)PT	E	AD		T N A	· · · - · · · · · · · · · · · · · · · ·	· · · · · · · · · · · · ·		
5619		К	<b>I</b> .o.b	P-PE	A		LP.	TA		K	E.V	
5631 5633		KEI.K. RA PEK	Б.А·	RTPS	B	K. E.A.QN.N 	ETS LH	N. PN K. N V V	1:12:12:11	· · · · · · · · · K ·	F.E.FG	D
6069	М-	- DTKI	· · · A	SPGI RC	AD	RY		T A V N	G			D
6230		V PATI	1:1	SP-AA- A-	V	<b>A</b>		T	11 <b>-</b> 11-111		F	
6231 3085		RDR.S.K.	і	RPTAD- RC RPAS	A Q.B	K. R OE	R	T		· · · · · · · · · · · · · · · · · · ·		RKE
3968	R.	KE. K	. DOA-		D	QAR.	S	TSSSVV		<b>L</b> M		
5478		.V	Al	(AV	A		L.TN	T		K	F	
5578 5585		STI	A(	GT	P	A	L.N	N	· · · - · · - · · ·	· · · · · · · · · · · · ·	.NA.V	
5492		G		SPGI RC	T	DRY	<b>L</b>	T	s			
5691			IAK.	P		UD		NHPS T.EA	. D D		V S.FG	
5896		.VT	<b>Т</b> .К.		D		· · · · · · · · · · · · · · · · · · ·	NH.T	· · · = · · = · · · ·	· · · · · · · · ¤ · ·	A.V	E
6050	R.	V PI		RPAA	D	E.		N			v	
											J	
	PAK	-bdg T	hioeste	erase-bdg			B-COP?	AP-interactio	on <u>V</u> 1H			
Nefcon	PAK 121 GLIYSOKR	-bdg T QX ILDLWVYHTQ	hioeste GYFP	erase-bdg DWQNYT P(	GPGIRXP	LT FGWCFKLVPV	B-COP: XPEKVEEANE	AP-interactio	on VIH SQHGMDDPEK	EVLMWKFDS	R LAFEHMAREI	. HPEYYKDC
Nefcon 3477 5122	PAK 121 GLIYSOKR	-bdg T OX ILDLWVYHTO E	hioeste GYPP	erase-bdg DWQNYT P(	SPGIRXP	LT FGWCFKLVPV	B-COP XPEKVEEANE D.D E. I.A	AP-interactio	DE VIH	EVLMWKFDSH	R LAFEHMAREI	HPEYYKDC
Nefcon 3477 5122 5542	PAK 121 GLIYSORR	-bdg T OX ILDLWVYHTO .2 .2	hioeste GYFP	erase-bdg DWQNYT P(	GPGIRXP Y P	LT FGWCFKLVPV	ß-COP? XPEKVEEANE D.DA D.JA	AP-interactio	N VIH SQHGMODPEK	EVLMWKFDSI	R LAFEHMAREI	HPBYYKDC D F.N.
Nefcon 3477 5122 5542 5565 5661	PAK GLIYSOKR W.D	-bdg T OX ILDLWVYHTO .E .D .D	bioeste GYFP F	erase-bdg DWQNYT P(	SPGIRXP Y. P V.Y. T.F	LT FGWCFKLVPV ILYE	6-COP XPEKVEEANE D.D. E.I.A D.E.NTA D.E.K	AP-interactio	n VIH SQHGMDDPEK .L. C. R .L. R N	EVLMWKFDSI I E K.R.N.I K.Q.S	R LAFHHMAREI H .K.V. I L .E. IR S .LR.I. F	HPBYYKDC D F.N
Nefcon 3477 5522 5542 5565 5661 3551 3620	PAK 121 GLIYSOKR W. D. K.	-bdg T DX ILDLWVYHTO E I D D D D D I J I J I J I I I I I I I I I I I I I	hioeste GYPP F	erase-bdg DWQNYT Po	SPGIRXP Y Y F VY T F	LT FGWCFKLVPV I.LYE L.IYE	β-COP <sup>2</sup> <u>XPEKVEEANE</u> <u>D.D.</u> <u>A</u> <u>D.E.K.</u> <u>E.E.NTA</u> <u>D.E.K.</u> <u>E.O.</u>	P-interactio	N VIH SQHGMDD PEK L E R N R EDR	EVLMWKFDS E K.R.N.I K.Q.S V V R	R LAFHHMAREI 	. НРБҮҮКОС 
Nefcon 3477 5122 5542 5565 5661 3551 3620 5549	PAK 121 GLIYSQKR 	-bdg T DX ILDLWVHTO .2	hioeste GYPP F	erase-bdg DWQNYT P	GPGIRXP Y Y Y Y Y Y Y Y F Y Y	LT FGWCFKLVPV I.LYE L.IYE	β-COP' XPEKVEEANE D.D	P AP-interactio	N VIH SQHGMDD PEK L E R N R BDR	EVLMWKFDSI E K.R.N.I K.Q.S V V R.I I	R LAFHHMAREI K.V. I. E. IR S. LR.I. F B. R. V.	HPEYYKDC D P N
Nefcon 3477 5122 5542 5565 5661 3620 5549 5549 5549 5549 5549	PAK 121 GLIYSOKR W. D. K. VH. V. K. VH. V. R. H. B.	-bdg T DX ILDLWVYBTO .E	bioeste GYPP - F - F - F	erase-bdg DWQNYT P(	GPGIRXP Y Y Y Y Y F Y F Y Y Y	LT FGWCFKLVPV I.LYE L.IYE	8-COP XPEKVEEANE D.D	AP-interactio	n VIH SQHGMDDPEK L. E. R. N	EVLMWKFDSI E K.R.N.I K.Q.S V V.R.I I I Q.I	R LAFHHMARBI HK.V. L .E. IR S .LR.I. F HR. K .L.T.KV	HPBYYKDC D F N O PF F
Nefcon 3477 5122 5565 5661 3551 3620 5549 5796 5958 5958 5969 6017	PAK. 121 GLIYSOKR W. D. K. VH	-bdg I DX ILDLWVYHTO Z I D D D N D N D N D N D N D N D N D N D N D N D N D N D N D N N D N N N N N N N N N N N N N	bioeste GYPP F	erase-bdg DwQNYT Po D	GPGIRXP Y Y Y Y Y Y Y Y Y Y Y Y Y Y	LT FGWCFKLVPV I L L L L	6-COP XPEXVEEANE D.D B.BNTA B.BNTA B.O D.DVT B.O D.DVT B.O D.DVT D.DVT D.DVT	AP-interactio GENNCLLHPM R. D R. DN S	N VIH SQHGMDDPEK L E R L N R N R AL C R C R	EVLMWKPDSI F K.R.N.I K.Q.S V. V.R.I I I V.R.I V. V.R.I I V. V. V. V. K. V. V. V. V. V. V. V. V. V. V. V. V. V.	R LAFHHMAREI K.V. I. E. IR L.R. I. R. V. K. L. T. KV. BR T. BR T.	PP P P P P P
Nefcon 3477 5122 5542 5565 5661 3551 3620 5549 5796 5958 5958 5958 6017 6056	PAK. 121 GLIYSOKR VH VH VH H R K VF R K	-bdg I DX ILDLWVYHTQ Z I D D D D D N D N D N C N D N D N D N D N D N D N D N D N D N D N N N N N N N N N N N N N	hioeste GYPP F F	erase-bdg DwQNYT Po D	SPGIRXP Y Y P V Y Y Y Y Y Y Y Y Y Y Y Y Y	LT FGWCFKLVPV I L.LYB L.I L L	B-COP? XPEKVERANE D.D B B B. B B. B B. B MTA B. D C. D D.D D.D D.D D.D MTA D.D MTA D.D MTA D.D MTA MTA MTA MTA MTA MTA MTA MTA	AP-interaction GENNCLLAPM A. D. N. S. S. Y. I.	N VIH SOHGMOD PEK L. E R L. B R BDR N. R BDR N. R C. R C. R C. R C. R	EVLMWKFDSI E K.R.N.I K.Q.S V V.R.I I V.R.I Q.I V V.R.Z C R.C C	R LAFHHMARBI S K V. E I. S LR I F R . C L T KV R I R I R I V V V	HPBYYKDC D P N Q PP P P P Q P
Nefcon 3477 5122 5565 5661 3620 5549 5756 5958 5959 6017 6056 6116 6129	PAK 121 GLIYSOKR W. D. K. VH V. K. VF R. K. D. T	-bdg I 2 2 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0	hioeste GYPP F	Prase-bdg DWQNYT Pr D	SPGIRXP Y Y Y Y Y Y Y Y Y Y Y Y Y	LT FGWCFKLVPV I L L I L L L L L L	B-COP? XPEKVERANE D.D S B B. B B. B B B B B B B C B C C C C D C D C D C D C D C D C D D C D C D C D D C D D D C D	AP-interaction	n VIH SOHGMODPEK L. B. R. N	EVLMWKFDSE E K.R.N.I K.Q.S V V.R.I I U R.C R C	R LAPHHMARBI K V. F. J. E. J. J. LR. I. F. R. J. K. V. R. J. R. J. R. J. R. J. R. R. R.	HPBYYKDC D P N Q PP P P P N
Nefcon 3477 5542 5565 5661 3551 3620 5549 5796 5598 6056 6127 6056 6129 6296 6301	PAK 121 GLIYSOKR V V K	-bdg I 2 2 0 1 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0	bioeste GYPP F	Hase-bdg DVONYT P D D	SPGIRXP Y Y Y Y Y Y Y Y Y Y Y Y Y	LT FGWCFKLVPV I.LYE L.IYE I.L	B-COP XPEKVERANE D.D S. I B B B D.D D.G. S K.T S	AP-interaction GENNCLLEPM R. DN R. DN S. V I I I I S	N VIH SOHGMODPEK L. B. R L. B. R L. B. R BDR AL. C. R L. B. C. N. I. B. C. I. B. C. I. B. C. I. B. S. C.	EVLMWKFDSE E K.R. N.I K.Q.S V.R.I Q.I V. Q. R.C Q. C C C C	R LAPHHMAREI K.V. I. E. IF S.LR.I.F R.J. C.L.T.KV. RR.I.T. RR.I. V. RR.I. V. RR.I. V. R. R. V. V. R. R. V. V. V. V. V. V. V. V. V. V	HPBYYKDC D P N Q PP P P P N D ON P
Nefcon 3477 5542 5565 5661 3551 3620 5549 5796 5796 55969 6017 6056 6129 6296 6129 6296 6399 6296	PAK 121 GLIYSOKR P W W W K V R K V R K C V K K	-bdg I 2 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	hioeste GYPP F	erase-bdg DWQNYT P D D C	SPGIRXP Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	LT PGWCFKLVPV I.LYE L.LYE .C.	B-COP XPEKVERANE D.D. K. B. J. MTA D. B. K. B. C. MTA D. J. MTA D. J. MTA MTA MTA MTA MTA MTA MTA MTA	AP-interactio	N VIH SOHGMON PEK L S R N BDR N BDR N R L S C J S C S R N S C S R S S S S S S S S S S S S S S S S S S	EVLMWKPDS R R N 1 K R N 1 V R 1	R LAPHHMARBI K.V. I E II S LR I.F R. I C.L.T.KV. RR I.T.F R. R. RK I.T.F V. R. RK I.K.	PP P P P P P P P P P P P P P P P P P P
Nefcon 3477 5542 5565 5661 3551 3550 5595 55958 5958 5958 5958 5958 5958	PAK. 121 GLIYSOKR W. W. GLIYSOKR V. K. V. K. K. V. K. K. K. K. K. K. K. K. K. K	-bdg I DX ILDLWYHTO .2 .2 .2 .2 .2 .2 .2 .2 .2 .2	Hioeste GYPP F F F	rase-bdg DWQNYT P D.	SPGIRXP Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	LT PGWCFKLVPV I LYE L IYE I I	6-COP XPEKVEBANE D.D	AP-interaction GENNCLLHPM D. B. D. S. S. J. S. J. J. J. J. J. J. J. J. J. J. J. J. J.	N         B           N         B           N         B           N         B           N         B           N         B           AL         G           L         B           SQL         B           SQL         B	EVLMWKPDS E K.R.N.I K.Q.S V.R.I I Q.I R C R C R C I R K.Q I V I V I V I V I V I V I V I V I V I	R LAFEHMAREI K V E K V E F R F R V C L T KV C L T KV C RR I R V R R V K K K K K K K C Q R	HPBYYKDC P P P OP N D ON P P P P P P P P P P P P P
Nefcon 3477 5542 5565 5661 3551 3520 5598 5595 6017 6056 6116 6116 6116 6116 6301 6349 6401 3478 5569 5405	PAK. 121 GLIYSOKR W. D. K. VH H. B. VF B. K. VF C. KD VF K. K. K. K. K. K. K. K. K. K.	-bdg I DX ILDLWVYHTO 2 D D D D D N N D N N D N N D N D N N D N N D N N D N N D N N D N N N D N N D N N D N N D N N D N N D N N D N N N D N N N D N N D N N N D N N D N N D N N D N N N D N N N D N N N D N N N N N N N D N N N N N N N N N D N N N N N N N N D N N N N D N N N N N D N N N N N D N N N N N N N N N N N N N	GYPP F F F	rase-bdg DWONYT P D D D C	SPGIRXP Y Y Y Y Y Y Y Y Y Y Y Y Y	LT FGWCFKLVPV I LYB L IYB C I C	B-COP: XPEKVERANE D.D	AP-interaction GENNCLLBPM D. R. DN S. V I I S. I I S. I I T. S. V V V V V V V V V V V V V V V V V V V	n VIH SQHGMDD PEK L. E. R. N	EVLMWKPDS EVLMWKPDS R R N 1 K Q S V R I I Q I V R I Q I V R I I R C C R C I R Q E R Q I V V P R P P	R LAFHHMARHI	PP PN PN PP PP PP PP PP PP PP PP PP PN
Nefcon 3477 5542 5565 5661 3551 5549 5549 5549 5549 6056 6116 6129 6296 6301 6349 6401 3478 5569 5319	PAK. 121 GLIYSOKR W. D. K. VH. R. K. VF. R. K. VF. R. K. VF. R. K. VF. R. K. VF. R. K. VF. R. K. VF. R. K. VF. R. VF. R. V. R. V. R. V. R. V. R. V. R. V. R. V. R. V. R. V. R. V. R. V. R. V. R. V. R. V. R. V. R. V. R. V. R. V. R. V. R. V. R. R. V. V. R. V. V. R. V. V. R. V. V. R. V. V. R. V. V. V. V. V. V. V. V. V. V	-bdg I D Z D D D D D D D D D D D N N D N N D N N D N N D N N D N N D N N D N N D N N D N N D N N D N N D N N D N N D N N D N N D N N D N N D N N N D N N N D N N N D N N N N N N N N N N N N N	Hioette GYPP F F F	rase-bdg DWONYT P D D C	5PGIRXP Y Y P T Y Y Y Y Y Y Y Y Y Y Y Y Y	LT FGWCFKLVPV I L L C C Y L	B-COP: XPEKVERANE D.D D.C. K. D.E. K. B. C D.D. VT. B D.D. VT. B	<ul> <li>AP-interaction</li> <li>GENNCLLAPM</li> <li>R.</li> <li>A.</li> <li>D.</li> <li>R.</li> <li>N.</li> <li>S.</li>     &lt;</ul>	N VIH SCHGMDD PEK L 8 R L 8 R N 8DR N 8DR N 8DR N 8DR N 8DR N 8DR C 8DR N 8DR C 8DR	EVLMWKFDSP K.R.N.I K.Q.S V.R.E I Q.F V.R.C I.V Q.F V.R.E I.R. K.Q.S I.V E.R.E E.S.S S.S.S.S S.S.S.S S.S.S S.S.S S.S.S S.S.S S.S.S S.S.S S	R LAFHHMARBI S. K. V. I. B. IR. I. R. R. R. R. R. V. R. R. V. R. R. V. R. V. R. V. R. V. V. R. V. V. V. V. V. V. V. V. V. V	HPBYYKDC P.N P.N PF PF PF PF PF PF PF PF PF PF
Nefcon 3477 5542 5565 3651 3651 3651 3651 3659 5958 5959 6056 6116 6126 6301 6349 6401 3478 5565 5319 5545 5517	PAK. 121 GLIYSOKR W. D. K. VH B. VF B. K. K. K. K. K. K. K. K. K. K	-bdg I DX ILDLWVYHTQ 2 D D D D D D N N D N D N N N D N N N D N N D N N D N N D N N D N N D N N D N N D N N D N N D N N D N N D N N D N N D N N D N N N D N D N N D N N D N D N D N D N N D D N N D N D N N D D N N D N D N D N D N D N D N D N D N D N D N N D D N D D N D D D N N D D D N N D D D N N D D D N N D D D N N D D N N D D D N N D D N N D D N N N D N N N D N	GYPP F F F F F F F F F F F F F F	rase-bdg DWONYT P D D G C	SPGIRXP Y Y Y Y Y Y Y Y Y Y Y Y Y	LT FGWCFKLVPV I L L C X X X L L L L L L L L L L L L L L	B-COP: XPEKVERANE D.D B	AP-interaction GENNCLLAPM 	N         R           N         R           N         R           N         R           N         R           N         R           C         R           I         B           C         R           C         R           C         R           C         B           C         B           C         B           R         C           R         C           L         B           L         B           C         I           R         C           R         C           R         C           R         C           R         C           R         C           R         C           R         C           R         C           R         C           R         R           R         R           R         R           R         R           R         R	EVLMWKFDSF E K.R.N.I K.Q.S V.V.F U Q.F Q.F Q.F Q.F Q.F C C R C C R C C E R E Z V R S C C S C C S C C S C S C S C S C S C	R LAFHHMARBI F K V. F L F. F L F. F L F. F L F. F R F.	HPBYYKDC D P N P P P P N D OP N D ON P P P P N P N P P P P P P P P P P P P P
Nefcon 3477 5542 55461 3551 3520 5598 5969 6056 6129 6296 6301 6349 6401 3478 5569 5519 5511 5541 5545 5519 5541 5545 5545	PAK 121 GLIYSOKR V. V. K. V. K. V. K. K. K. K. K. K. K. K. K. K	-bdg I DX ILDLWVYHTQ 2 D D D D D D D D D D D D D	hioeste GYPP F F F F F F F F F F F F F F F F	rase-bdg DWONYT P D D G G C	SPGIRXP Y Y Y Y Y Y Y Y Y Y Y Y Y	LT FGWCFKLVPV I L L I C X X M M X L L L I L L L L L L L L L L L L L L L	B-COP? XPEKVERANE D.D B B B. B B. B B. C B. C D. D D. S A D. A D. A D. A D. A D. A D. A D. A D. A D. A D. A D	AP-interaction GENNCLL IPM R D S S S S S T S S T S T S T S T S S T S T S T S T S T S T S T S T S T S T S T S S T S T S T S T S S T S S T S S S T S S S S S S S S S S S S S	N         R           N         R           N         R           N         R           N         R           N         R           C         R           I         B           C         R           C         R           C         R           C         R           C         R           C         R           C         R           C         R           L         B           C         I           L         R           C         R           L         R           C         R           D         R           C         R           D         R           R         R           R         R           R         R           R         R           R         R           R         R           R         R           R         R           R         R           R         R           R         R	EVLMWKFDSI E. K.R.N.I. K.Q.S. V. V.R.I. I. Q.I. V. R. Q. R. C. I. R. K.Q. V. R. V. V. R. V. R. V. R. V. R. V. R. V. R. V. R. V. R. V. R. V. V. R. V. R. V. V. R. V. V. V. V. V. V. V. V. V. V. V. V. V.	R LAFHHMARBI	HPBYYKDC D F N OP P P P P P P P P P P P P P
Nefcon 3477 5122 5542 55661 3521 3520 55968 5968 5969 6056 6116 6116 6116 6116 6301 6349 6349 5565 5515 5527 5541 5466 5535	PAK. CLIYSOKR CLIYSOKR VE VE VE VE K VE K VE K VF K VF K VF K VF K VF K VF K VF K VF K VF K VF K VF V K V K V V K V V K V V K V V K V V K V V K V V K V V K V V K V V K V V K V K V V K V V K K V V K K V V K K V V K K V V K K V V K K V V K K K V K K V K K V K K V K K V K K V K K V K K V K K V K K V K K V K K V K K V K K V K K V K K K K V K K K V K K K K K K K K K K K K K	-bdg I 2 2 0 1 0 1 0 1 0 0 0 0 0 0 1 1 0 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1	hioeste GYPP F F F F F F F F F F F F F F F	rase-bdg DWQNYT P D D G G C	GPGIRXP YPY YPY YPY YYY YYY YYY YYY Y	LT PGWCFKLVPV I L. LYB I L. LYB I L. L I	B-COP XPEKVEBANE D.DR D.BR B.B. NTA D.B. K. D.D. VT B.C T D.D. VT B.C T D.D. VT B.C T D.D. VT B.B. K D.D. K B.B. K D.D. K B.AEL K B.A	AP-interaction CENNCLLAPM R DN S V T S S T S S T S S T S S T S S T S S T S S T S S T S S T S S V S S S S S S S S S S S S S	N VIH SORGADI PEK L E R N BDR N BDR N BDR N BDR N BDR C B BD C B	EVLMWKPDS E R R R N V R I V R I V R I V R I V R I V V V R I V V V R I V V V R I V V V V V R I V V V V V V V V V V V V V	R LAFEHMAREI K V I LR I R V L T KV R R V R K K K K K K K K K K K K K	HPEYYKDC P N PP PP PP N D ON Y P P P N P N P N P N N
Nefcon 3477 5122 5542 55661 3521 3520 57966 5959 6056 6056 6017 6056 6017 6056 6017 6056 6017 6056 6049 6011 3478 5569 5513 5535 5535 5535 5535 5535 5535 553	PAK. 121 GLIYSO KR W. J. K. VI. K. V. K. K. K. K. K. K. K. K. K. K	-bdg I DX ILDLWVYHTO E D D D D D D D D D D D N N D N D N D N D N D N D N D N N D N D N D N D N D N N D N N D D N D N D D N D D N D D N D D N D D N D D N D D N D D N D D N D D N D D N D D D D D D D D D D D D D	hioest GYPP F F F F F F F	rase-bdg DWONYT P D D G G	GPGIRXP Y Y Y Y Y Y Y Y Y Y Y Y Y	LT PGWCFKLVPV L LYE L	β-COP XPEKVEEANE D.D	AP-interaction GENNCLL HPM A B D S S S S T S S T S S T S S T S S T S S T S S T S S T S S T S S T S S S S S S S S S S S S S	N         B           N         B           N         B           N         B           N         B           N         B           N         B           N         B           N         B           C         R           I         B           C         B           C         B           L         B           C         B           C         B           C         B           L         B           VB         B           C         B           L         B           N         B           N         B	EVLMWKPDS EVLMWKPDS K.R.N.I K.Q.S V.R.I I. Q. R C. R C. R C. R C. V. V. V. V. V. V. V. V. V. V	R LAFEHMAREI K V E K K V E F R F R F K K C L T KV C L T KV KV C L T KV C L T KV KV C L T KV C	HPEYYKDC D P N O P P P P P P P P P P P P P
Nefcon 3477 5542 5565 5661 3551 3551 3551 3551 6056 6129 6395 6305 6405 6405 6405 6405 6405 6405 6505 5515 5515 5515 5547 5547 5545 5555 555	PAK. 121 GLIYSO KR W W W W W W W W W W K K K K K K K K K K K K K	-bdg I DX ILDLWVYHTO 2 ILDLWVYHTO 2 I D N D N D N D N C N C N C N C N C N C N C N C	hioesta GYPP F F F F F F F F F F F	nase-bdg DWONYT P D D D D D D D C C C	GPGIRXP Y Y Y Y Y Y Y Y Y Y Y Y Y	LT FGWCFKLVPV I LYB L IYB C I C I I R I I R I L I R I L I I R	β-COP: XPEKVERANE D.D	<ul> <li>AP-interactio</li> <li>GENNCLLBPM</li> <li>D.</li> <li>R.</li> <li>D.</li> <li>S.</li> <li>V.</li> <li>S.</li> <li>I.</li> <li>S.</li> <l< td=""><td>N         R           N         R           N         R           N         R           AL         C           C         R           ML         S           R         R           AL         G           C         R           ML         S           C         R           C         R           C         R           C         R           C         R           C         R           C         R           C         R           C         R           C         R           R         R           C         R           R         R           R         R           R         R           R         R           R         R           R         R           R         R           R         R           R         R</td><td>EVLMWKPDS EVLMWKPDS R. R. N. 1 K. Q. S V. R. I Q. I V. R. I Q. I V. R. I E. R. S V. S</td><td>R LAFHHMAREI K.V. E.K.V. E.F. S.LR.I.F. B.R. R. C.L.T.KV. C.L.T.KV. C.L.T.KV. R. R. V. R. K.K. LK.I. C. R. C. C. C. C. C. C. C. C. C. C</td><td>HPBYYKDC PN PN O PF FF FF F P P P P P P N F N F N F N F N F N F N</td></l<></ul>	N         R           N         R           N         R           N         R           AL         C           C         R           ML         S           R         R           AL         G           C         R           ML         S           C         R           C         R           C         R           C         R           C         R           C         R           C         R           C         R           C         R           C         R           R         R           C         R           R         R           R         R           R         R           R         R           R         R           R         R           R         R           R         R           R         R	EVLMWKPDS EVLMWKPDS R. R. N. 1 K. Q. S V. R. I Q. I V. R. I Q. I V. R. I E. R. S V. S	R LAFHHMAREI K.V. E.K.V. E.F. S.LR.I.F. B.R. R. C.L.T.KV. C.L.T.KV. C.L.T.KV. R. R. V. R. K.K. LK.I. C. R. C. C. C. C. C. C. C. C. C. C	HPBYYKDC PN PN O PF FF FF F P P P P P P N F N F N F N F N F N F N
Nefcon 3477 5542 5565 5661 3551 3551 5549 5549 5549 5549 6126 6305 6401 3478 5569 6401 3478 5565 5515 5515 5545 5545 5545 5545 5545	PAK. 121 GLIYSCKR W. W. W. W. H. B. K. VF. K. VF. B. K. VF. K. VF. K. VF. K. VF. K. V. K. K. V. K. K. K. K. K. K. K. K. K. K	-bdg I DX ILDLWVYHTO 2 ILDLWVYHTO 2 I D N D N D N D N D N C N C N C N C N C N C N C N C	hioesta GYPP F F F F F F F F F F F	rase-bdg DWONYT P D D C S N	GPGIRXP Y Y Y Y Y Y Y Y Y Y Y Y Y	LT FGWCFKLVPV I LYE L LYE C L C L C L L L L L L L L L L L L L L L	β-COP: XPEKVEEANE D.D	<ul> <li>AP-interactio</li> <li>GENNCLLBPM</li> <li>D.</li> <li>R.</li> <li>D.</li> <li>R.</li> <li>D.</li> <li>S.</li> <li>Y.</li> <li>S.</li> <li>I</li> <li>S.</li>     &lt;</ul>	N         R           N         R           AL         S           C         R           AL         S           C         R           AL         S           C         R           L         B           C         R           L         R           C         R           C         R           C         R           C         R           C         R           C         R           C         R           C         R           C         R           L         R           C         R           C         R           L         R           R         R           L         R           N         A           N         A           N         A           N         A           R         R           C         B           C         B           R         R           C         B	EVLMWKFDS	R LAFHHMAREI K.V. E. II S.LR.I. F. R. R. R. R. R. R. R. R. R. R.	HPBYYKDC PN PN PF FF FF FF FF FN FN FN FN FN
Nefcon 3477 5542 5565 3651 3621 3651 3620 5969 6017 6056 6129 6296 6301 6349 6401 3478 5569 5515 5515 5515 5535 5505 5505 5505 5501 5633 5619 5633 5619 5633 5619 5633 5619 5633 5619 5633 5619 5633 5619 5633 5619 5633 5619 5633 5619 5633 5619 5633 5619 5633 5619 5633 5619 5633 5619 5635 5619 5542 5665 5655 5655 5655 5655 5655 5655	PAK. 121 GLIYSOKR V. V. K. VF 8. VF 8. K. V. K. K. V. K. K. V. K. K. V. K. K. V. K. K. K. K. K. K. K. K. K. K	-bdg I D X ILDLWVYHTQ Z I D D D D D N D N D N D N N D N N N N N N N N N N N N N	bioette GYPP F F F F F F F F F F F F F	rase-bdg DWONYT P D D C C	GPGIRXP Y Y Y Y Y Y Y Y Y Y Y Y Y	LT PGWCFKLVPV I LYB L LYB C L C L C L L L L L L L L L L L L L L L	B-COP: XPEKVERANE D.D	P. AP-interaction GENNCLL APM 	N         R           I         8           I         8           R         8           N         8           N         8           N         8           N         8           N         8           N         8           N         8           I         8           I         8           I         8           I         8           C         1           I         8           C         1           I         8           C         1           R         1           L         8           N         4           C         8           I         7           R         1           R         1           K         1	EVLMWKFDSF 	R LAFHHMAREI K.V. I. E. II S. LR. I. R. R. R. R. R. V. R. V. R. V. R. V. R. V. R. V. R. V. S. R. K. K. V. S. R. R. V. V. S. R. K. V. S. R. K. V. S. R. K. V. S. R. K. V. S. R. K. V. S. R. K. V. S. R. K. V. S. R. K. V. S. R. K. V. S. R. K. V. S. R. K. V. S. R. K. V. S. R. K. V. S. R. K. V. S. R. K. K. V. S. R. K. K. K. K. K. K. K. K. K. K	HPBYYKDC 
Nefcon 3477 5122 5542 5565 5961 3521 3521 3521 5549 5549 5549 5549 5549 5549 5549 6056 6116 6301 6301 6301 6301 6349 6401 3478 5541 5545 5515 5545 5545 5545 6401 5541 5541 5541 5541 5541 5541 5542 5542	PAK. 121 GLIYSOKR W. D. K. VH B. VF B. K. K. K. K. K. K. K. K. K. K	-bdg I D X ILDLWVYHTQ Z D D D D D D N N D N D N D N D N D N N D N N D N N D N D N D N D N D N D N D N D N D N D D N D D N D D N D D N D D N D D N D D N D D N D D N D D N D D N D D N D D N D D D N D D D N D D D N D D D D D D D D D D D D D	hioette GYPP F F F F F F F F F F F F F	rase-bdg DWONYT P D D G G C	3PGIRXP Y Y Y Y Y Y Y Y Y Y Y Y Y	LT PGWCFKLVPV I L L C C L L L L L L L L L L L L L L L	B-COP: XPEKVERANE D.D B B B B B B B B B B B B D. S D. S S D. A S	P. AP-interaction GENNCLL APM A. D. S. S. S. S. S. S. S. S. S. S. S. S. S.	n VIH SOHGMOD PEK L 8 R L 8 R N 8 R C 8 R C 8 R C 8 C 8 C 8 C 8 C 8 C 8 C 8 C 8	EVLMWKFDSF E K.R.N.1 K.Q. S V.R. F I. V.R. F V. C. C. C. C. C. C. C. C. C. C	R LAFHHMARBI F. K. V. F. I. F. I. S. I.R. I. F. I.R. I. F. R. I. R. V. C. L. T. KV. R. V. R. V. V. R. V. V. R. V. V. R. V. V. R. V. V. R. V. V. R. V.	HPBYYKDC D P N P P P P P P P P P P N P P N P N P N P N P N P N P N P N N D OP N N D OP N N D OP N D OP N D OP N D OP N D OP N D OP N D OP N D OP N D OP N D OP N D OP N D OP D OP D OP D OP D OP D OP D OP D ON P P N D ON P P N D ON P P N D ON P P N D ON P P N D ON P P N D ON P P N D ON P P N P P N P P N P P N P P N P P N P P P N P P N P P P N P P N P P P N P P P N P P P N P P P N P P P N P P P N P P P N P N
Nefcon 3477 5122 5542 55661 3520 55968 5969 5076 60566 6116 6301 6301 6301 6301 6301 6301 63	PAK. 121 GLIYSO KR VH VH VH K VF K VF K VF K VF K K VF K VF K K VF K V K V K V K V K V K V K V K V K V K V K V K K V K V K K V K K V K K V K K K K K K K K K K K K K	-bdg T DX ILDLWVYHTQ E I D	hioesta GYPP F F F F F F F F F F F F F F F	rase-bdg DWONYT P D D G G C	GPGIRXP Y Y Y Y Y Y Y Y Y Y Y Y Y	LT PGWCFKLVPV I L. JYB L. I I C. JYB I V V L. I L L L L L L L L L L L L L L L L L L L	6-COP XPEKVEEANE D.D	AP-interaction GENNCLLEPM A B D S S S S S S S S S S S S S	N         R           N         R           N         R           N         R           N         R           N         R           N         R           N         R           N         R           I         R           I         R           C         R           I         R           C         B           C         B           C         R           L         R           L         R           N         A           C         B           C         B           K         G           L         R           K         G           L         R           N         A           K         G           L         R           R         R           R         R           R         R	EVLMWKPDSP 	R LAFEHMAREI K V I I R R V K C R R V R R V R R V R K K K K K K K K K K K K K	HPEYYKDC D P N O P P P P P P P P P P P P P
Nefcon 3477 5542 5565 5661 3551 3551 3551 3551 3557 6017 6016 6129 6401 3478 3478 3478 3478 3478 5595 5515 5515 5515 5515 5515 5515 551	PAK. 121 GLIYSO KR W. J. K. VH. K. H. R. VF. R. K. VF. K. VF. K. VF. K. VF. K. VF. K. VF. K. VF. K. VF. K. K. VF. K. K. VF. K. K. V. K. K. K. K. K. K. K. K. K. K	-bdg I DX ILDLWVYHTO E D D D D D D D D D D D D D	hioesta GYPP F F F F F F F F F F F F F F F F F F	nase-bdg DWONYT P D D D D D C C	GPGIRXP Y Y Y Y Y Y Y Y Y Y Y Y Y	LT PGWCFKLVPV I LYE I YE I YE I I I I R L I R L I R L I R L I R L	β-COP?           XPEKVERANE           D.J.           B	AP-interaction          GENNCLLIPM         A         D         R         D         R         S         S         S         T         S         T         S         T         S         S         T         S         T         S         T         S <td>N         B           N         B           N         BDR           C         R           L         B           C         B           C         B           C         B           C         B           C         B           C         B           L         B           N         A           C         B           L         B           K         G           L         B           K         G           L         B           K         G           L         R           K         G           L         R           N         R           R         R           R         R           N         R           R</td> <td>EVLMWKPDSP </td> <td>R LAFEHMAREI K V I K V K V K V K V K V K V K V K V</td> <td>HPEYYKDC P N P N O PP PP PP P P P P P P P P P</td>	N         B           N         B           N         BDR           C         R           L         B           C         B           C         B           C         B           C         B           C         B           C         B           L         B           N         A           C         B           L         B           K         G           L         B           K         G           L         B           K         G           L         R           K         G           L         R           N         R           R         R           R         R           N         R           R	EVLMWKPDSP 	R LAFEHMAREI K V I K V K V K V K V K V K V K V K V	HPEYYKDC P N P N O PP PP PP P P P P P P P P P
Nefcon 3477 5542 5565 5661 3551 3551 3551 3551 6056 6129 6056 6129 6056 6129 6056 6129 6056 6129 6056 6129 5545 5315 5315 55478 55478 55478 5631 5633 5619 5633 6193 669 6193 669 6193 669 6193 669 6193 5635 5635 5635 5635 5635 5635 5635 56	PAK. 121 GLIYSO KR W W W W W B K V V K K K K K K K K K K K K K	-bdg I DX ILDLWVYHTO 2 ILDLWVYHTO 2 I D N D N D N D N D N C N C N C N C N C N C N C N C	hioente GYPP F F F F F F F F F F F F F F	nase-bdg	SPGIRXP Y Y Y Y Y Y Y Y Y Y Y Y Y	LT FGWCFKLVPV I LYE L YE C L C X Y L I R I R I R L L L L L L L L L L L L L L L L L L L	β-COP?           XPEKVERANE           D. J	AP-interaction          GENNCLLBPM         D.         R.         D.         S.         V         S.         V         S.         S.         T.         S.         S.         T.         S.         S.         T.         S.	N         R           N         R           N         R           AL         C           C         R           M         R           AL         G           C         R           M         R           AL         G           C         R           M         R           C         R           C         R           C         R           C         R           C         R           C         R           C         R           C         R           C         R           C         R           R         R           R         R           R         R           R         R           R         R           R         R           R         R           R         R           R         R           R         R           R         R           R         R           R         R           R         R	EVLMWKPDS 	R LAFEHMAREI K.V. I. B. IF S.LR.I. B. R. C.L.T.KV. C.L.T.KV. C.L.T.KV. S. RR.I. R. V. R. K. K. K. K. K. K. K. K. K. K	HPBYYKDC PN PN PF PF PF PN PN PN PN PN PN PN PN PN PN
Nefcon 3477 5542 5565 5561 3551 3551 3551 5542 5542 5542 5542 5542 5547 5541 5545 5515 5515 5515 5515 5515	PAK. 121 GLIYSCKR W. D. K. VH. K. VF. B. K. VF. K. VF. B. K. VF. K. VF. K. VF. K. VF. K. V. K. C. K. V. K. K. V. K. K. V. K. K. K. K. K. K. K. K. K. K	-bdg I DX ILDLWVYHTO E D D D D D N N D D D D D D D D D D D D D	hioente GYPP F F F F F F F F F F F F F F F F F	rase-bdg DWONYT P D D D C C	GPGIRXP Y Y Y Y Y Y Y Y Y Y Y Y Y	LT FGWCFKLVPV I LYE L LYE C L C L C L C L C L C L C L C L C L L L L	β-COP: XPEKVEEANE D.D	AP-interaction          GENNCLLAPM         D.         R.         D.         S.         V.         S.         V.         S.         V.         S.         V.         S.         T.         S.         T.         S.         T.         S.         T.         S.         S. <t< td=""><td>N         R           N         R           AL         S           C         R           M         R           AL         G           C         R           M         R           AL         G           C         R           L         B           C         R           L         R           C         R           L         R           C         R           L         R           C         R           L         R           C         R           L         R           C         R           L         R           C         R           L         R           K         G           L         R           K         G           L         R           N         R           R         R           N         R           R         R           R         R           R         R           R         R</td><td>EVLMWKFDS</td><td>R LAFHHMAREI K V B K C L T K K C L T KV C C R C R C R C R C R C R C R C</td><td>HPEYYKDC PN PN PF FF FF FN FN FN FN FN FN FN F</td></t<>	N         R           N         R           AL         S           C         R           M         R           AL         G           C         R           M         R           AL         G           C         R           L         B           C         R           L         R           C         R           L         R           C         R           L         R           C         R           L         R           C         R           L         R           C         R           L         R           C         R           L         R           K         G           L         R           K         G           L         R           N         R           R         R           N         R           R         R           R         R           R         R           R         R	EVLMWKFDS	R LAFHHMAREI K V B K C L T K K C L T KV C C R C R C R C R C R C R C R C	HPEYYKDC PN PN PF FF FF FN FN FN FN FN FN FN F
Nefcon 3477 5125 5542 5565 33210 35796 5969 6017 60566 6116 6301 6309 6206 6301 6349 6401 3478 5569 5515 5515 5515 5505 5505 5505 5505 5602 5613 5613 5613 5631 5633 5619 5633 5619 5535 5505 5505 5505 5505 5505 5505 550	PAK. 121 GLIYSQ KR V V R V V R K V V R R V V K K V V R R V V K K V V R R V V K V V R R V V V R R V V V R R V V K R V V V K R R R R R R R R R R R R R	-bdg I D X ILDLWVYHTQ Z ILDLWVYHTQ Z I D D D D D N D N N N N N N N N N N N N N	hioesta GYPP F F F F F F F F F F F F F F F F F F	rase-bdg DWONYT P D D C C	GPGIRXP Y Y Y Y Y Y Y Y Y Y Y Y Y	LT FGWCFKLVPV I LYB L LYB C L C L C L C L C L C L L C L L L L L L	B-COP: XPEKVERANE D.D B B B B B B B B B B B B B B B B D S D S D S D S D S D D S D S D S B D S B D S D. D D. D. D D. D	AP-interaction          GENNCLLBPM         A         D         R         D         S         I         I         S         S         I         S         I         S         S         I         S         I         S         I         S         I         S         I         S         I         S         I         S         I         S         I         S         I         S         S         S         S         S         S         S         S         S         I         S         S         I         S         I         S         I         S         I         S         I         S <td>n VIH SCHGADD PEK L 8 R L 8 R L 8 R R SC 8 N 8 C 8 N 8 C 8 N 8 C 8 N 8 C 8 N 8 C 9 N 9 C 9 N 9 C 9 N 9 C 9 N 9 C 9 N 9 C 9 N 9 C 9 S 0 C 1 8 S 0 C 1 8 C 1 8 S 0 C 1 8 C 1 8 C</td> <td>EVLMWKFDSP</td> <td>R LAFHHMAREI K.V. I. B. IR I. R. I. R. R. R. R. R. V. K. L. T. KV. R. V. R. V. S. R. V. R. V. S. R. V. S.</td> <td>HPBYYKDC P N P N PF FF OF N D ON FF FN FN FN FN FN FN FN FN F</td>	n VIH SCHGADD PEK L 8 R L 8 R L 8 R R SC 8 N 8 C 8 N 8 C 8 N 8 C 8 N 8 C 8 N 8 C 9 N 9 C 9 N 9 C 9 N 9 C 9 N 9 C 9 N 9 C 9 N 9 C 9 S 0 C 1 8 S 0 C 1 8 C 1 8 S 0 C 1 8 C	EVLMWKFDSP	R LAFHHMAREI K.V. I. B. IR I. R. I. R. R. R. R. R. V. K. L. T. KV. R. V. R. V. S. R. V. R. V. S. R. V. S.	HPBYYKDC P N P N PF FF OF N D ON FF FN FN FN FN FN FN FN FN F
Nefcon 3477 5542 5565 33210 5549 5596 5958 5958 6017 6056 6116 6301 6301 6301 6349 6401 3478 5515 5515 5515 5515 5549 6401 3478 5549 6401 3478 5549 6401 3478 5549 6401 3478 5549 6401 3478 5549 6401 5549 6401 5549 6401 5549 6401 5549 6401 5549 5549 6401 5549 5549 6401 5549 6401 5549 6401 5549 6401 5549 6401 5549 6401 5549 6401 5549 6401 5549 6401 5549 6401 5549 6401 5549 6401 5549 6401 5549 6401 5549 5549 6401 5549 5549 5549 6401 5549 5549 5549 6401 5549 5549 5549 5549 6401 5549 5549 6401 5549 5549 5549 5549 6401 5549 5549 5549 6401 5549 5549 6401 5549 6401 5549 6401 5549 6401 5549 6401 5559 5549 6401 5549 6401 5559 6401 5559 6401 5559 6401 5559 5559 5549 5559 5549 5559 5549 5559 5549 5559 5549 5559 5549 55555 5559 555555	PAK. 121 GLIYSO KR V V K V K V K V K V K V K V K V K V K V K V K V K V K V K V K V K K K V K K K K K K K K K K K K K	bdg         I           D         ILDLWVYHTQ           Z         I           D         N           D         N           D         N           D         N           D         N           D         N           D         N           D         N           D         N           D         N           D         N           D         N           D         N           D         N           D         N           D         N           D         N           E         N           D         N           E         N           D         N           D         N           D         N           D         N           D         N           D         N           D         N           D         N           D         N           D         N           D         N           D         N           D <t< td=""><td>hioesta GYPP F F F F F F F F F F F F F F F F F F</td><td>rase-bdg DWONYT P D D C C</td><td>GPGIRXE           VPYPY           VPYPY           VT           VT      &lt;</td><td>LT PGWCFKLVPV I LYE L LYE C L C X M I R C L L L L L L L L L L L L L L L L L L L</td><td>B-COP XPEXVEEANE D.D</td><td>AP-interaction CENNCLLAPM R DN R DN S V I I S V I I S V I I S V I I S V I S V I I S V I S V I S V I S V I S V I S V I S V I S V I S V I I S V V V V V V V V V V V V V V</td><td>N VIH SUBGADD PEK L E R L E R R L E R SUBGADD PEK R R L E R C R N R C R N R C R N R C R N R C R C R C R C R C R C R C R C</td><td>EVLMWKPDS EVLMWKPDS R. R. N I V. R. I V. R. I O. I V. R. I V. I V. I V. I V. I V. I V. I V. I V.</td><td>R LAFEHMAREI K V I LR I R LR I R V K C L T KV R R V R R K K K K K K K K K K K K K</td><td>HPBYYKDC D P N P P P P P P P P P P P P P</td></t<>	hioesta GYPP F F F F F F F F F F F F F F F F F F	rase-bdg DWONYT P D D C C	GPGIRXE           VPYPY           VPYPY           VT           VT      <	LT PGWCFKLVPV I LYE L LYE C L C X M I R C L L L L L L L L L L L L L L L L L L L	B-COP XPEXVEEANE D.D	AP-interaction CENNCLLAPM R DN R DN S V I I S V I I S V I I S V I I S V I S V I I S V I S V I S V I S V I S V I S V I S V I S V I S V I I S V V V V V V V V V V V V V V	N VIH SUBGADD PEK L E R L E R R L E R SUBGADD PEK R R L E R C R N R C R N R C R N R C R N R C R C R C R C R C R C R C R C	EVLMWKPDS EVLMWKPDS R. R. N I V. R. I V. R. I O. I V. R. I V. I V. I V. I V. I V. I V. I V. I V.	R LAFEHMAREI K V I LR I R LR I R V K C L T KV R R V R R K K K K K K K K K K K K K	HPBYYKDC D P N P P P P P P P P P P P P P
Nefcon 3477 5122 5542 5565 5961 3520 5598 5969 5016 6016 6116 6301 6301 6301 6301 6301 6	PAK. 121 GLIYSO KR VH V V K VF K VF K VF K K VF K K VF K K K K K K K K K K K K K	-bdg T OX ILDLWVYHTO E D D D D D D D D D D D D D D D D D D	hioeste GYPP B B B B B B B B B B B B B B B B B B	nase-bdg DVONYT P D D G G C	GPGIRXP Y Y Y Y Y Y Y Y Y Y Y Y Y	LT PGWCFKLVPV I L. JYB L. JYB I . J I . J C . J I . R I . R I . R I . R I . R I . L J I . R I . L J I . L J J J J J J J J J J J J J J J J J J J	β-COP?           XPEKVERANE           D. J	AP-interaction          GENNCLLEPM         R         R         R         NCLLEPM         R         N         S         V         S <t< td=""><td>N         SUBCHOND PEK           L         E         R           L         E         R           L         E         R           N         B         B           N         R         R           L         B         SO           N         R         R           L         B         SO           C         R         R           L         B         SO           C         B         R           L         R         R           L         R         R           L         R         R           L         R         R           L         R         R           L         R         R           L         R         R           N         A         R           L         R         R           N         A         R           L         R         R           N         A         R           N         A         R           N         A         R           N         A         R     </td></t<> <td>EVLMWKFDSF E. K. R. N. I. K. Q. S. V. R. I. Q. I. Q.</td> <td>R LAFEHMAREI K V L K V R L T KV C L T KV KV C L T K</td> <td>HPEYYKDC D P P P P P P P P P P P P P</td>	N         SUBCHOND PEK           L         E         R           L         E         R           L         E         R           N         B         B           N         R         R           L         B         SO           N         R         R           L         B         SO           C         R         R           L         B         SO           C         B         R           L         R         R           L         R         R           L         R         R           L         R         R           L         R         R           L         R         R           L         R         R           N         A         R           L         R         R           N         A         R           L         R         R           N         A         R           N         A         R           N         A         R           N         A         R	EVLMWKFDSF E. K. R. N. I. K. Q. S. V. R. I. Q.	R LAFEHMAREI K V L K V R L T KV C L T KV KV C L T K	HPEYYKDC D P P P P P P P P P P P P P
Nefcon 3477 5542 5565 5661 3551 3551 3551 3551 3551 3551	PAK. 121 GLIYSO KR W W W K VH K K VF K K K K K K K K K K K K K	-bdg         I           D         ILDLWVYHTO           E         I           D         N           D         N           D         N           D         N           D         N           D         N           D         N           D         N           D         N           D         N           D         N           D         N           D         N           Z         N           D         N           Z         N           D         N           Z         N           D         N           Z         N           D         N           Z         N           Z         N           D         I           D         I           D         I           D         I           D         I           D         I           D         I           D         I           D         I      I         D	hioente GYPP F F F F F F F F F F F F F F F F F F	nase-bdg	GPGIRXP Y Y Y Y Y Y Y Y Y Y Y Y Y	LT PGWCFKLVPV L LYE L	β-COP?           XPEKVERANE           D. J	P. AP-interaction          GENNCLLIPM         A         B         B         S	N         SUBCHOUD PEK           L         E         R           L         E         R           L         E         R           N         BDR         BDR           N         R         R           L         E         R           N         R         R           L         B         S           C         R         R           L         B         S           C         B         R           L         R         R           L         R         R           L         R         R           L         R         R           L         R         R           L         R         R           L         R         R           N         A         R           N         A         R           N         A         R           N         A         R           N         A         R           N         A         R           N         A         R           N         A         R </td <td>EVLMWKPDS EVLMWKPDS K.R.N.I K.Q.S V.R.I I Q.I Q.I R. C. E. B. V.R.S V.S V.S V.S V.S V.S V.S V.S V</td> <td>R LAFEHMAREI K.V. B. K.V. C. L. T.KV. C. L. T.KV. C. L. T.KV. C. RR. I. T. R. C. RR. I. T. R. C. R. V. B. R. C. R. C. R.</td> <td>HPEYYKDC   _</td>	EVLMWKPDS EVLMWKPDS K.R.N.I K.Q.S V.R.I I Q.I Q.I R. C. E. B. V.R.S V.S V.S V.S V.S V.S V.S V.S V	R LAFEHMAREI K.V. B. K.V. C. L. T.KV. C. L. T.KV. C. L. T.KV. C. RR. I. T. R. C. RR. I. T. R. C. R. V. B. R. C. R. C. R.	HPEYYKDC   _

FIG. S2. Alignment of consensus HIV-1 Nef amino acid sequences. Newly derived Nef sequences are aligned with their overall consensus sequence, with dots indicating identity and dashes gaps introduced to optimize the alignment. Nef sequences are color coded as in Fig. 1, with red indicating *-35CChi*, blue *-35CClow*, green *-35TThi* and black *-35TTlow* subjects, respectively. For patient 5466, only the predominant Nef sequence is shown. Some conserved sequence elements in Nef, the position of the polypurine tract (PPT), and the start of the 3' long terminal repeat (LTR) are indicated. bdg, binding; VIH, catalytic subunit of vacuolar ATPase.



FIG. S3. Modulation of MHC-I by Nef in primary PBMCs. (Left) Quantitative assessment of Nef-mediated downmodulation of MHC-I on human PBMCs. Similar results were obtained using PBMC from a different donor. (Right) Correlation between the efficiency of Nef-mediated downmodulation of MHC-I in Jurkat T cells and PBMCs.



FIG. S4. Cell type dependent effect of Nef on early T cell activation. Levels of (A) CD69 and (B) CD25 expression by Jurkat cells, PBMCs and primary  $CD4^+$  T cells infected with HIV-1 IRES/eGFP constructs. The expression levels are given relative to those measured for the *nef* defective control HIV-1 construct which was set to 100%. PBMCs and CD4<sup>+</sup> T cells were derived from two different donors (A and B).

Code	Group	A1	A2	C1	C2	B1	B2	DRB1	DRB2	DQA1	DQA2	DQB1	DQB2	DPA1	DPA2	DPB1	DPB2
276	-35CC/sVLh	*2301	*3201	*0202	*0602	*4002	*5001	*0301	*1501	*0102	*0501	*0201	*0602	*0103	*0201	*0402	*1101
497	-35CC/sVLh	*2402	*3002	*0202	*0501	*1801	*2705	*0301	*1101	*0501	*0501	*0201	*0301	*0103	*0103	*0201	*0202
533	-35CC/sVLh	*6801	*6801	*0602	*0602	*4701	*5001	*0301	*0701	*0201	*0501	*0201	*0201	*0103	*0103	*0201	*1501
590	-35CC/sVLh	*0201	*2402	*0501	*0602	*3701	*4402	*0402	*0701	*0201	*0301	*0302	*0303	*0103	*0201	*0201	*0501
605	-35CC/sVLh	*0201	*3301	*0501	*0802	*1402	*4402	*0102	*0401	*0101	*0301	*0301	*0501	*0103	*0202	*0401	*0501
608	-35CC/sVLh	*0205	*3101	*0602	*1402	*5001	*5101	*0701	*0801	*0201	*0401	*0201	*0402	*0103	*0201	*0401	*1001
731	-35CC/sVLh	*0201	*0201	*0501	*0602	*4402	*5801	*0101	-	*0101	*0102	*0501	*0609	*0103	*0103	*0301	*0401
841	-35CC/sVLh	*0201	*0201	*1203	*1402	*4901	*5101	*1101	*1601	*0102	*0501	*0301	*0502	*0103	*0103	*0201	*0401
959	-35CC/sVLh	*0101	*3101	*0202	*0202	*4002	*5101	*0801	*1301	*0103	*0401	*0402	*0603	*0103	*0103	*0401	*0401
1216	-35CC/sVLh	*2402	*2902	*0303	*0602	*2705	*5001	*0401	*0701	*0201	*0301	*0201	*0302	*0103	*0201	*0401	*1401
1231	-35CC/sVLh	*3001	*3201	*0602	*1203	*1302	*3901	*0701	*0901	*0201	*0301	*0201	*0303	*0103	*0103	*0201	*0401
1402	-35CC/sVLh	*0301	*2402	*0802	*1203	*1402	*3801	*0102	*1101	*0101	*0501	*0301	*0501	*0103	*0103	*0401	*0402
1443	-35CC/sVLh	*2301	*2402	*0202	*1402	*5101	*5101	*0401	*1103	*0301	*0501	*0301	*0302	*0103	*0103	*0201	*0402
1529	-35CC/sVLh	*0101	*3201	*0602	*1203	*1302	*1801	*1501	*1601	*0102	*0102	*0502	*0602	*0103	*0103	*0301	*2301
103	-35CC/sVLl	*2301	*3201	*0202	*0602	*4002	*5001	*0301	*1501	*0102	*0501	*0201	*0602	*0103	*0201	*0402	*1101
640	-35CC/sVLl	*0301	*3301	*0802	*1203	*1402	*3901	*0102	*1601	*0101	*0102	*0501	*0502	*0103	*0201	*0401	*1001
707	-35CC/sVLl	*0201	*3002	*0102	*0802	*1402	*5101	*0102	*1501	*0101	*0102	*0501	*0602	*0103	*0103	*0201	*0201
1516	-35CC/sVLl	*3303	*6801	*0501	*1202	*4402	*5201	*1301	*1502	*0103	*0103	*0601	*0603	*0201	*0202	*0401	*1001
111	-35TT/sVLh	*0101	*2402	*0701	*0701	*0801	*1517	*0101	*1302	*0101	*0102	*0501	*0604	*0103	*0103	*0401	*0402
123	-35TT/sVLh	*0201	*0201	*0501	*0702	*0702	*5101	*0401	*0404	*0301	*0301	*0302	*0302	*0103	*0103	*0301	*0601
163	-35TT/sVLh	*0201	*3201	*0102	*1602	*5101	*5601	*1101	*1302	*0102	*0501	*0301	*0604	*0103	*0103	*0201	*0401
525	-35TT/sVLh	*1101	*2601	*0701	*0701	*0801	*1801	*0301	*1601	*0102	*0501	*0201	*0502	*0103	*0201	*0401	*1001
526	-35TT/sVLh	*2501	*2501	*0701	*0701	*0801	*0801	*0301	*0301	*0501	*0501	*0201	*0201	*0201	*0201	*0101	*0101
537	-35TT/sVLh	*2301	*2601	*0303	*1505	*0705	*1501	*0701	*1501	*0102	*0201	*0201	*0602	*0103	*0201	*0402	*1401
546	-35TT/sVLh	*0201	*0301	*0401	*0702	*0702	*3501	*0401	*1101	*0301	*0501	*0301	*0301	*0103	*0103	*0401	*0401
554	-35TT/sVLh	*0201	*0201	*0303	*0303	*1501	*1501	*0401	*0401	*0301	*0301	*0302	*0302	*0103	*0103	*0401	*0401
585	-35TT/sVLh	*0101	*0201	*0401	*0701	*0801	*5101	*0301	*0301	*0501	*0501	*0201	*0201	*0103	*0103	*0401	*0401
614	-35TT/sVLh	*0101	*0301	*0701	*0702	*0702	*0801	*0301	*0701	*0201	*0501	*0201	*0201	*0103	*0103	*0201	*0401
638	-35TT/sVLh	*0201	*1101	*0303	*0702	*0702	*5501	*1001	*1401	*0101	*0101	*0501	*0503	*0103	*0103	*0401	*0401
1171	-35TT/sVLh	*2501	*3101	*0304	*0702	*0702	*4001	*0404	*1501	*0102	*0301	*0302	*0602	*0103	*0103	*0201	*0401
1294	-35TT/sVLh	*1101	-	*0701	*1502	*1517	*5101	*0404	*1601	*0102	*0301	*0302	*0502	*0103	*0103	*0401	*0402
1332	-35TT/sVLh	*0301	*2402	*0401	*0702	*0702	*3501	*0801	*1101	*0401	*0501	*0301	*0402	*0103	*0103	*0301	*0601
1334	-35TT/sVLh	*0201	*0301	*0701	*0702	*0702	*5101	*1301	*1501	*0102	*0103	*0602	*0603	*0103	*0103	*0201	*0301
313	-35TT/sVLl	*0201	*2501	*0304	*0701	*0801	*1501	*0301	*0401	*0301	*0501	*0201	*0302	*0103	*0201	*0101	*0401
1477	-35TT/sVLl	*0201	*0301	*0304	*0401	*1501	*3501	*0101	*0401	*0101	*0301	*0302	*0501	*0103	*0201	*0402	*1001
162	-35TT/sVLl	*0301	*3002	*0304	*0701	*5703	*1510										

**TABLE S1**. HLA types of HIV-1-infected individuals analyzed.

				Recepto	T cell act	ivation <sup>b</sup>						
Group	MHC-I	HLA-A	HLA-B	HLA-C	CD4	CD28	CXCR4	CD74	NF-AT	CD69	Infectivity <sup>c</sup>	Repl.(%) <sup>d</sup>
-35CC/sVLh (n=19)	5.1±0.3	3.7±0.3	3.7±0.3	1.7±0.1	3.8±0.2	1.5±0.1	1.6±0.1	5.0±0.4	124±12	95±3	8.0±0.7	133±12
-35CC/sVLl (n=6)	4.6±0.6	3.5±0.5	3.6±0.5	1.8±0.2	2.9±0.2	1.2±0.1	1.4±0.1	3.1±0.7	195±21	98±5	4.8±0.6	136±32
-35TT/sVLh (n=19)	6.0±0.6	4.2±0.5	4.2±0.5	2.0±0.2	3.7±0.3	1.6±0.1	1.5±0.1	5.6±0.6	174±12	101±3	6.4±0.5	170±13
-35TT/sVLl (n=5)	4.9±0.6	3.1±0.3	3.1±0.4	1.7±0.4	4.8±0.3	1.6±0.1	1.9±0.3	5.2±1.2	218±59	107±6	6.8±1.1	165±22

TABLE S2. Functional activity of HIV-1 nef alleles from -35TT or -35CC individuals with high or low set-point viral loads.

<sup>a</sup> N-fold down-modulation of CD4, CD28, CD3, MHC-I, MHC-II and up-regulation of Ii surface expression levels were determined as described in the Materials and Methods. In all analyses at least 500 HIV-1-infected (GFP+) cells were analyzed. Shown are average values derived from three to five independent experiments (±SD).

<sup>b</sup> Values were determined as described in the legend to Fig. 5.

<sup>c</sup> Shown is the n-fold enhancement of viral infectivity compared to the *nef*-deleted HIV-1 NL4-3 control construct. Values represent the average of three measurements ( $\pm$ SD).

<sup>d</sup> The efficiency of virus spread was determined in PBMC and is shown relative to the proviral HIV-1 NL4-3 Nef (*nef*+) construct (100%)